ATTR-CM became a multi-option disease state.
Acoramidis and vutrisiran approvals changed ATTR-CM from late recognition to sequencing, selection, and monitoring strategy.
CardiovascularCardiomyopathyHeart failureDevices
Cardiovascular
As of June 2026, cardiovascular research is splitting into measurable disease states: ATTR-CM has new stabilizer and silencer options, Lp(a) outcome trials are testing inherited-risk modification, renal denervation and pulsed-field ablation have moved into adoption questions, and genetic cardiomyopathy programs are asking whether molecular mechanism can route therapy.
Domain research lens
This page tracks the signals that change cardiovascular buyer decisions: genotype-to-mechanism routing, biomarker-defined risk, device adoption, heart-failure endpoints, and whether a measurable cardiovascular state changes outcomes.
June 2026 field state
A field moving from population-risk averages to measurable state routing.
The strongest work asks whether genetics, imaging, biomarkers, rhythm substrate, nerve activity, and cardiometabolic state can route earlier and more specific cardiovascular decisions.
Cardiomyopathy, heart failure, arrhythmia, vascular biology, cardiometabolic risk, cardiac devices, genetic disease, and measurable cardiovascular outcome gates.
The domain thesis: cardiovascular value is created when a measurable state changes the treatment choice, not when a biomarker merely describes risk.
Device therapies are being judged after approval.
Renal denervation and pulsed-field ablation now need patient selection, workflow, durability, reimbursement, and real-world safety evidence.
Risk modification still needs outcomes.
Lp(a) lowering, genetic cardiomyopathy correction, fibrosis reversal, and AI-ECG risk calls all need endpoint-linked benefit.
Recent research signals
The 2025-2026 update is a decision-gate wave.
Each signal below starts from the field: what changed, why it matters, and which research or buyer decision becomes more testable.
ATTR-CM treatment choice became a sequencing problem.
FDA approved acoramidis for ATTR-CM in 2024 and vutrisiran for ATTR-CM in 2025, adding stabilizer and RNA-silencing choices to the treatment landscape.
Why it matters
Cardiomyopathy programs now need genotype, stage, symptom, biomarker, and endpoint logic before therapy selection.
Decision implication
Changes ATTR-CM diligence from product availability to routing and monitoring.
HELIOS-B analyses keep the first-line question active.
Alnylam announced additional HELIOS-B analyses for Heart Failure 2026 to characterize vutrisiran across ATTR-CM patient profiles and concomitant therapies.
Why it matters
The field needs comparative and real-world logic for stabilizers, silencers, background therapy, and disease burden.
Decision implication
Changes whether buyers treat ATTR-CM as one indication or a routed portfolio.
Lp(a) lowering is waiting for outcomes, not biology.
Large Phase 3 outcomes trials, including pelacarsen and olpasiran programs, are testing whether inherited Lp(a) risk modification reduces cardiovascular events.
Why it matters
Lp(a) is measurable and causal, but the buyer decision turns on event reduction, population selection, and treatment threshold.
Decision implication
Keeps risk-biomarker programs gated on outcomes.
Renal denervation and pulsed-field ablation moved from approval to use-case proof.
FDA-approved renal denervation systems and pulsed-field ablation systems are changing hypertension and atrial fibrillation workflows.
Why it matters
The hard questions are selection, durability, operator learning, reimbursement, complications, and comparison against optimized standard care.
Decision implication
Changes device diligence from approval status to deployment economics.
What leading groups are working on
The current edge is a set of validation programs, not a single breakthrough story.
These representative programs and research fronts frame the active field before the page maps Zemi Dossiers into it.
ATTR-CM
Stabilizer-versus-silencer sequencing
Acoramidis, vutrisiran, and tafamidis make ATTR-CM a routed-treatment landscape: genotype, disease stage, biomarkers, symptoms, and background therapy all affect choice.
Lp(a)Inherited-risk modification waits on event reduction
Pelacarsen and olpasiran outcome trials are testing whether large Lp(a) reductions lower coronary death, myocardial infarction, and other hard cardiovascular events.
Hypertension devicesRenal denervation after approval
FDA-approved renal denervation systems now face the practical questions: patient selection, medication background, durability, operator learning, reimbursement, and real-world BP control.
ElectrophysiologyPulsed-field ablation moves into first-line evidence
PFA is being evaluated not only for noninferiority against thermal ablation but for workflow, safety, recurrence detection, and first-line value versus antiarrhythmic drugs.
Genetic diseaseCardiomyopathy routing by mechanism class
Sarcomere, desmosomal, metabolic, amyloid, and mitochondrial cardiomyopathies need different logic for addition, silencing, editing, small molecules, and device avoidance.
Decision gates
What must be true before a buyer should build, fund, partner, monitor, avoid, or run the next study.
These are field-level gates first. The dossier library appears later as the set of existing Zemi products that can help investigate them.
Mechanism routing
Does the genotype or state imply addition, silencing, editing, small molecule, device, or avoidance?
Endpoint hierarchy
Which endpoint decides benefit: biomarker, imaging, hospitalization, exercise capacity, rhythm, or mortality?
Stage selection
Is the patient early enough for modification and advanced enough for measurable benefit?
Device durability
Does benefit persist after operator learning and real-world selection bias?
Risk biomarker utility
Does a measurable risk signal change outcomes, not just prognosis?
Safety reserve
Are arrhythmia, conduction, vascular, renal, or off-target risks bounded?
Zemi Dossiers in this domain
The dossiers sit where new research creates hard buyer decisions.
Each dossier card uses stats from the actual research report manifest and Evidence & Decision Workbook, including pages, workbook sheets, evidence/source rows, claim rows, power rows, and decision instruments where present.
Primary Zemi Dossier
Genetic Cardiomyopathy Precision Therapies
Uses molecular mechanism rather than gene label to route programs toward addition, knockdown, editing, or avoidance logic.
Why it belongs here
Which genetic cardiomyopathy programs match mechanism, modality, delivery, safety window, and evidentiary standard well enough to advance?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Fibrosis as Failed Resolution
Identifies the rate-limiting resolution node and the matched research move across persistence, scar integrity, and reversal measurement.
Why it belongs here
Which fibrosis programs target the binding resolution node, and what would show whether repair can occur without destabilizing tissue integrity?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
AI Clinical Validation & Digital Biomarkers
Turns AI and digital biomarkers into validation-gate questions: prospective utility, generalization, drift, fairness, and endpoint acceptance.
Why it belongs here
Which AI or digital-biomarker claims are ready for prospective validation, and which are still retrospective performance stories?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Perfusable Vascular Networks
Evaluates whether vascular networks are merely visible, truly perfusable, functionally mature, and integration-ready.
Why it belongs here
Which biofabrication programs have moved from structural vascular patterns to perfusable, mature, functional integration evidence?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Xenotransplantation Durability Ceiling
Maps the durability ceiling across host tolerance, organ-specific failure physiology, immune compatibility, and organ-scale function.
Why it belongs here
Which xenotransplantation programs are limited by host tolerance, organ-specific failure physiology, perfusion, or immune compatibility rather than edit count?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Mitochondrial Medicine Permanence Ladder
Maps mitochondrial interventions onto a permanence ladder so buyers do not overbuild or underbuild the required correction.
Why it belongs here
Which mitochondrial programs need transient support, durable shift, editing, replacement, or avoidance based on heteroplasmy and tissue constraints?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Watchlist
Signals that would change the map in 2026-2028.
These are the developments most likely to change the field map, evidence posture, or next-study priorities.
Lp(a)
Phase 3 outcomes and treatment thresholds
Event data will decide whether Lp(a) is a treated causal risk factor or a high-confidence biomarker still waiting for utility.
Genetic cardiomyopathyTherapy data by mechanism class
Programs need to separate toxic gain, haploinsufficiency, aggregate, sarcomere, and metabolic failure before modality choice.
ATTR-CMReal-world sequencing of stabilizers and silencers
The next field map depends on stage-specific benefit, monitoring markers, cost, background therapy, and combination evidence.
Device durabilityRenal denervation and PFA after broad adoption
Cardiovascular devices need real-world durability once patient selection, operator skill, and reimbursement constraints enter.
Field-note discipline
Current-state pages need a source-aware update layer.
The public page stays readable, but the underlying domain model tracks source-linked developments that change evidence posture, buyer decisions, or next-study priorities.
2024-2025 / ATTR-CM
ATTR-CM is no longer a single-product market.
The relevant question is now sequencing and patient-state routing across stabilizers, silencers, and background heart-failure care.
2026 / Lp(a) Lp(a) is a hard-outcome waiting room.Biology and measurement are strong, but program value changes only when outcomes establish who should be treated and at what threshold.
2026 / Devices Approval is not the same as adoption proof.RDN and PFA are now judged by workflow, durability, safety, patient selection, and payer acceptance.
From domain signal to Zemi Dossier
Request access to inspect the full research report, Evidence & Decision Workbook, power calculations, and release-audit surfaces behind each decision package.